Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MapLight Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding MapLight Therapeutics, Inc.’s stock price such as:

• MapLight Therapeutics, Inc.’s current stock price and volume
• Why MapLight Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for MPLT from analysts
• MPLT’s stock price momentum as measured by its relative strength

About MapLight Therapeutics, Inc. (MPLT)

Before we jump into MapLight Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer’s disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson’s disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Want to learn more about MapLight Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MapLight Therapeutics, Inc..

MapLight Therapeutics, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, MapLight Therapeutics, Inc.’s stock price was $11.210.

MapLight Therapeutics, Inc. is down 0.18% from its previous closing price of $11.230.

During the last market session, MapLight Therapeutics, Inc.’s stock traded between $11.065 and $11.610. Currently, there are approximately 45.43 million shares outstanding for MapLight Therapeutics, Inc..

MapLight Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MapLight Therapeutics, Inc. Stock Price History

MapLight Therapeutics, Inc.’s (MPLT) price is currently down 13.9% so far this month.

During the month of August, MapLight Therapeutics, Inc.’s stock price has reached a high of $13.740 and a low of $10.840.

Over the last year, MapLight Therapeutics, Inc. has hit prices as high as $40.430 and as low as $9.100. Year to date, MapLight Therapeutics, Inc.’s stock is down 36.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MapLight Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there was 1 analyst who downgraded MapLight Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate MapLight Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MapLight Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MapLight Therapeutics, Inc. (MPLT) by visiting AAII Stock Evaluator.

Relative Price Strength of MapLight Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, MapLight Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how MapLight Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MapLight Therapeutics, Inc. Stock Price: Bottom Line

As of August 21, 2026, MapLight Therapeutics, Inc.’s stock price is $11.210, which is down 0.18% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MapLight Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.